1. Home
  2. NMRA vs POET Comparison

NMRA vs POET Comparison

Compare NMRA & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • POET
  • Stock Information
  • Founded
  • NMRA 2019
  • POET 1972
  • Country
  • NMRA United States
  • POET Canada
  • Employees
  • NMRA N/A
  • POET N/A
  • Industry
  • NMRA
  • POET Semiconductors
  • Sector
  • NMRA
  • POET Technology
  • Exchange
  • NMRA Nasdaq
  • POET Nasdaq
  • Market Cap
  • NMRA 287.6M
  • POET N/A
  • IPO Year
  • NMRA 2023
  • POET N/A
  • Fundamental
  • Price
  • NMRA $0.64
  • POET $4.42
  • Analyst Decision
  • NMRA Buy
  • POET Strong Buy
  • Analyst Count
  • NMRA 8
  • POET 2
  • Target Price
  • NMRA $9.29
  • POET $6.25
  • AVG Volume (30 Days)
  • NMRA 876.3K
  • POET 541.4K
  • Earning Date
  • NMRA 05-12-2025
  • POET 05-14-2025
  • Dividend Yield
  • NMRA N/A
  • POET N/A
  • EPS Growth
  • NMRA N/A
  • POET N/A
  • EPS
  • NMRA N/A
  • POET N/A
  • Revenue
  • NMRA N/A
  • POET $41,427.00
  • Revenue This Year
  • NMRA N/A
  • POET $9,379.33
  • Revenue Next Year
  • NMRA N/A
  • POET $684.42
  • P/E Ratio
  • NMRA N/A
  • POET N/A
  • Revenue Growth
  • NMRA N/A
  • POET N/A
  • 52 Week Low
  • NMRA $0.62
  • POET $1.60
  • 52 Week High
  • NMRA $17.19
  • POET $7.79
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 27.87
  • POET 60.61
  • Support Level
  • NMRA $0.73
  • POET $4.10
  • Resistance Level
  • NMRA $0.72
  • POET $4.50
  • Average True Range (ATR)
  • NMRA 0.06
  • POET 0.22
  • MACD
  • NMRA 0.02
  • POET 0.05
  • Stochastic Oscillator
  • NMRA 4.91
  • POET 78.50

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: